Autopsy report · NCT06424236
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
Cause of deathOther
“DIAN-TU announced the discontinuation of the DIAN-TU-001 OLE based on the status of the drug program and findings from an interim efficacy analysis and.”
Life of this trial
- Registered 3 years 10 months after it had already started.
- Ran for about 3 years 5 months before it stopped.
- 73 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Conditions
- Alzheimers Disease; Dementia; Alzheimers Disease, Familial
- Interventions
- Gantenerumab
- Participants
- 73
- Sites
- 17
- Countries
- Australia, France, Puerto Rico, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.